• Precision medicine and future therapeutics.
• Classifications and risk factors.
• Historical milestones.
• Acute Myeloid Leukaemia.
• Acute Lymphoblastic Leukaemia.
• Chronic Myeloid Leukaemia.
• Myeloproliferative neoplasms.
• Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
• Leukaemias of mature B and T/NK cells.
• Hodgkin Lymphoma.
• Non-Hodgkin Lymphoma.
• Plasma cell neoplasms.
• Principal treatment-related side-effects.
• Concluding thoughts.
Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.
• Includes the latest research and classification
• includes a useful survey of how the subject has evolved to date
• includes a chapter on side-effects of treatments
Tariq I Mughal, MD, FRCP, FACP, graduated in medicine from St George's Hospital Medical School, London, and trained in hematology, medical oncology and stem cell transplantation at the University of Colorado Health Sciences Center, Denver. He is Clinical Professor of Medicine at Tufts University School of Medicine, Boston, Consultant Hematologist at Kings College NHS Foundation Trust, London, Professor of Hematology and Oncology at the University of Buckingham Medical School, UK, and the founder of Apline Oncology Foundation.